The efficacy of different follow-up strategies in clinical stage I Non-seminomatous Germ Cell Cancer: a Markov simulation study
- PMID: 15964134
- DOI: 10.1016/j.eururo.2005.04.021
The efficacy of different follow-up strategies in clinical stage I Non-seminomatous Germ Cell Cancer: a Markov simulation study
Abstract
Objective: There is no universally accepted standard protocol for surveillance of patients with clinical stage I Non Seminomatous Germ Cell Tumors (CS I NSGCT). Prospective studies to compare different follow-up policies have not been performed, even though a great deal of time and resources is spent in surveillance. In this study, we constructed a Markov model to evaluate the impact of different follow-up strategies on disease-specific mortality (DSM) and life expectancy (LE) of patients with CS I NSGCT.
Methods: A discrete time non-homogeneous semi-Markov model was used to simulate different follow-up strategies for a hypothetical population of CS I NSGCT patients. Estimates of the model parameters were based on the literature. Output parameters were DSM and LE. Three different strategies were compared: (1) the intensive The Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NCI/AvL) protocol; (2) the European Association of Urology (EAU) protocol; and (3) a hypothetical minimal protocol (i.e. follow-up limited to the first two years). Furthermore, we evaluated the impact of abdominal CT scans and chest X-rays on DSM.
Results: Comparing with the EAU protocol (DSM: 3.05%; LE: 53.3 years), the intensive NCI/AvL protocol leads to a 1.2% lower DSM and a 6 months higher LE (DSM: 1.81%; LE: 53.9 years). The hypothetical follow-up scenario during the first two years shows a DSM of 6.83% and an LE of 51.4 years. Abdominal CT scans of the retroperitoneal lymph nodes appear to be important, while chest X-rays have little impact on DSM.
Conclusion: A follow-up policy limited to the first two years will result in an unacceptable high percentage of death from disease (6.83%). The relatively small benefit of an intensive follow-up protocol as proposed by the NCI/AvL, compared to that of the EAU, must be weighed against its economic and psychological costs. Our model suggests that CT-scanning is essential for a low DSM, whereas the large number of X-rays seem to have little additional effect.
Similar articles
-
Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres.Can J Urol. 2005 Apr;12(2):2575-80. Can J Urol. 2005. PMID: 15877938
-
Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis.J Clin Oncol. 2010 Jan 1;28(1):119-25. doi: 10.1200/JCO.2009.22.0400. Epub 2009 Nov 16. J Clin Oncol. 2010. PMID: 19917846
-
Effect of routine follow-up after treatment for laryngeal cancer on life expectancy and mortality: results of a Markov model analysis.Cancer. 2007 Jan 15;109(2):239-47. doi: 10.1002/cncr.22401. Cancer. 2007. PMID: 17154185
-
Surgical management of low-stage nonseminomatous germ cell testicular cancer.BJU Int. 2009 Nov;104(9 Pt B):1362-8. doi: 10.1111/j.1464-410X.2009.08860.x. BJU Int. 2009. PMID: 19840014 Review.
-
Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective.Eur Urol. 2008 Nov;54(5):1004-15. doi: 10.1016/j.eururo.2008.08.022. Epub 2008 Aug 13. Eur Urol. 2008. PMID: 18722704 Review.
Cited by
-
Survival analysis of children with stage II testicular malignant germ cell tumors treated with surgery or surgery combined with adjuvant chemotherapy.Chin J Cancer. 2015 Feb;34(2):86-93. doi: 10.5732/cjc.014.10027. Epub 2014 Oct 17. Chin J Cancer. 2015. PMID: 25322864 Free PMC article.
-
[Results of the randomised phase III study of the German Testicular Cancer Study Group. Retroperitoneal lymphadenectomy versus one cycle BEP as adjuvant therapy for non-seminomatous testicular tumours in clinical stage I].Urologe A. 2009 May;48(5):523-8. doi: 10.1007/s00120-008-1927-7. Urologe A. 2009. PMID: 19183929 Clinical Trial. German.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical